Campath -1 H

Emerging Frontline Therapy in Chronic Lymphocytic Leukemia

Kanti R. Rai, Janet Stephenson

128 pages, parution le 15/03/2001

Ajouter à une liste

Indisponible

Résumé

This is the only authoritative, detailed clinical reference on Campath-1H, which stands alone among monoclonal antibodies because its reciprocal antigen CD52 is expressed in diverse cell types, and its further potential for clinical practice in hemato-oncology in the treatment of B-cell chronic lymphocytic leukemia. It records the development and actions of Campath-1H, presents the unique clinical, immunological and molecular features of B-cell chronic lymphocytic leukemia, and explores the potential of Campath-1H as frontline therapy for patients with B-CLL. The book contains five main chapters on B-cell chronic lymphocytic leukemia, the road to remission (from single agent intervention to combination therapy and onward), monoclonal antibodies in cancer (the development of Campath-1H), Campath-1H in B-CLL (remissions of refractory disease), and the role of Campath-1H prior to bone marrow transplant in refractory B-CLL plus a concluding chapter on future perspectives. Includes bibliographic references and index.

Sommaire

Introduction
B-cell chronic lymphocytic leukemia: Molecular Basis and Prognostic Markers
The road to remission: from single agent intervention to combination therapy and onward
Monoclonal antibodies in cancer: the development of Campath-1H
Campath-1H in B-CLL: remissions of refractory disease
The role of Campath-1H prior to bone marrow transplant in refractory B-CLL
Future perspectives

Voir tout

Replier

Caractéristiques techniques

	PAPIER
Éditeur(s)	Chapman and Hall / CRC
Auteur(s)	Kanti R. Rai, Janet Stephenson
Parution	15/03/2001
Nb. de pages	128
Couverture	Broché
Poids	500g
Intérieur	Noir et Blanc
EAN13	9781842140604
ISBN13	978-1-8421-4060-4